Professional Traders

[PoemStone]

ROSG. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
http://ih.advfn.com/p.php?pid=nmona&article=53879232

website. http://www.rosettagenomics.com/

Corporate Overview. 2012
 Share Capital
– 8.2M ordinary shares outstanding
– 390K warrants (wt. avg. exercise price – approx. $29/share)
– 36K options (wt. avg. exercise price – approx. $81/share)
– No convertible securities outstanding
 Cash
– Funds from recent financings:
– $1.4 million Registered Direct (April 12, 2012); 540,000* shares at $2.55/share
– $2.2 million Registered Direct (May 16, 2012); 632,057 shares at $3.50/share
– $6.6 million Registered Direct (May 24, 2012); 570,755 shares at $11.50/share
17
– $27.5 million from underwritten offering (August 2012); 5.5M shares at $5.00/share
– Sufficient to fund operations for >24 months
 Burn Rate
– Quarterly operating expenses of approximately $1.5 million
– Revenues from mets2 expected to reduce burn rate over next several quarters
 Debt Retirement
– Company paid off its entire $1.75M senior secured debenture
– Zero debt on the balance sheet
http://www.rosettagenomics.com/admin/SiteImages/file/Rosetta%20Corporate%20Overview%20-%208%2017%2012.pdf